Search

A patent has been issued for Galectin-3 plasmapheresis therapy by Eliaz Therapeutics Inc., focusing on selectively treating agents in a mammal's blood outside of its body to address various disease conditions. The therapy involves removing galectin-3 from a patient's bloodstream to treat inflammation, fibrosis, and cell proliferation. Apheresis is used to withdraw blood, separate components, treat them outside the body, and return them to the patient, offering new avenues for personalized treatment strategies. [Extracted from the article]

A patent has been issued for compositions and methods for plasmapheresis by Lyfspn Inc., focusing on improving health status through measuring pre- and post-treatment indicators like strength, balance, mental status, and walking ability. The method involves administering plasmapheresis to individuals to treat conditions associated with aging, such as loss of strength, balance, and diminished ability to walk. Plasmapheresis is used to modulate the expression of cell surface markers on white blood cells, aiming to reduce cellular senescence. The patent outlines specific steps and embodiments for implementing these methods. [Extracted from the article]

A study conducted at Hospital Italiano de Buenos Aires in Argentina focused on the use of eculizumab as a first-line treatment for children with complement factor H antibody-mediated hemolytic uremic syndrome (HUS). The research involved four children aged 6-11 years old who showed improvement in hematological signs and kidney function after receiving eculizumab. The study suggested that a short course of eculizumab, along with immunosuppressive agents, may be effective in reversing thrombotic microangiopathy symptoms and improving kidney function in patients with severe FH antibody-mediated HUS. [Extracted from the article]

Researchers at the Second Affiliated Hospital in Guangdong, China have published a comprehensive review on the latest developments in improving the blood compatibility of hemoperfusion adsorbents. They found that advanced coating and modification techniques, such as albumin-collodion, cellulose, hydrogel, and heparin coatings, have led to significant enhancements in blood compatibility across different types of adsorbent materials. However, challenges remain in terms of manufacturing processes and costs, which limit the broad clinical application of these advancements. Future efforts should focus on cost-benefit analysis, large-scale production strategies, exploring blood-material interactions, and developing innovative technologies for safer and more effective blood purification therapies. [Extracted from the article]

A patent has been issued for a system, method, and apparatus for monitoring, regulating, or controlling fluid flow in medical applications such as intravenous infusion therapy, dialysis, transfusion therapy, and nutrition therapy. The invention includes a flow meter with optical sensors to monitor fluid flow, a valve to regulate fluid flow, and the ability to remotely control the flow rate. The patent provides detailed descriptions of the methods and devices involved in monitoring and controlling fluid flow. This information is useful for researchers and practitioners in the field of medical treatment involving fluid delivery systems. [Extracted from the article]

A patent application has been filed for a protein-based method that can block neutralizing antibodies (NAbs) and improve gene therapy delivery. The method involves using a protein called Mycoplasma protein M to prevent NAbs from neutralizing the therapeutic gene delivery agent, adeno-associated virus (AAV). This approach has shown promise in laboratory and animal studies and could potentially overcome the challenge of pre-existing NAbs in patients. The protein M method may also have applications in treating autoimmune disorders and disorders associated with excess antibodies. The patent application provides detailed information on the modified protein and its mutations, as well as fusion proteins and vectors encoding the protein. This information may be useful for researchers in the fields of biotechnology, immunology, and gene therapy. [Extracted from the article]

This document provides information about a clinical trial for a gene therapy treatment called delandistrogene moxeparvovec (also known as SRP-9001 or ELEVIDYS) for individuals with Duchenne muscular dystrophy (DMD). The trial is currently not recruiting participants and aims to enroll 16 male children between the ages of 4 and 8. The treatment involves a single intravenous infusion of delandistrogene moxeparvovec after a plasmapheresis procedure, provided that certain antibody levels are sufficiently low. The trial is being conducted by Sarepta Therapeutics, Inc. in the United States. [Extracted from the article]

The document provides information about an ongoing clinical trial in the Russian Federation, NCT06602245, which aims to evaluate the impact of using the Efferon LPS device during hemoperfusion on the clearance of antibacterial drugs in patients with sepsis. Sepsis is a global health issue, and while extracorporeal methods have shown promise in treating septic shock, the potential removal of life-saving drugs like antibiotics through hemoperfusion is not well understood. The study is currently in the recruitment phase and plans to enroll 30 participants, with data collection expected to be completed by September 30, 2025. [Extracted from the article]

A recent case study conducted at the Jewish General Hospital in Quebec, Canada, explores the treatment of osmotic demyelination syndrome (ODS), a rare complication resulting from the rapid correction of severe chronic hyponatremia. The study focuses on the use of intramuscular botulinum toxin injections to target spasticity in ODS patients. The case study describes a 40-year-old male with a history of panhypopituitarism who experienced significant improvement in his condition, including reduced spasticity and regained ability to ambulate with assistance, after receiving the botulinum toxin injections. The study highlights the limited treatment options available for ODS and suggests that botulinum toxin injections may be a potential alternative for managing ODS-related spasticity that is unresponsive to other treatments. [Extracted from the article]

Researchers at Nankai University in Tianjin, China have developed a novel hemoperfusion adsorbent for effectively cleansing bilirubin from plasma. The adsorbent, based on molecularly imprinted polymers (MIPs), demonstrated high specificity and adsorption capacity for bilirubin. It also exhibited lower hemolysis rates, higher cell viabilities, and excellent anticoagulant properties compared to clinical adsorbents. The researchers believe that this approach shows promise for bilirubin cleansing and can be applied to develop other hemoperfusion adsorbents. The research has been peer-reviewed and published in the Chemical Engineering Journal. [Extracted from the article]

A patent has been issued to Fenwal Inc. for systems and methods for optimizing the volume of plasma collected during plasmapheresis procedures. Plasmapheresis is a process in which whole blood is withdrawn from a donor, the plasma is separated from the cellular components, and the cellular components are returned to the donor. The patent describes a method for collecting the maximum volume of raw plasma permitted by FDA guidelines, taking into account the donor's hematocrit and other factors. By optimizing the volume of plasma collected from each donor, the efficiency of plasma collection centers can be improved. The patent includes a system for implementing this method, which involves a separator, donor line, anticoagulant line, touchscreen, and controller. [Extracted from the article]

A recent study conducted at Aga Khan University Hospital in Karachi, Pakistan, explored the use of therapeutic plasmapheresis as a potential treatment for pediatric acute liver failure (PALF). PALF is a severe condition with high mortality rates, and currently, liver transplant is the only specific therapy available. The study found that plasmapheresis, a procedure that removes metabolites and other substances that accumulate due to impaired liver function, showed promising results in improving clinical outcomes for three critically ill patients with acute liver failure. However, further research is needed to fully understand the potential benefits of this approach. [Extracted from the article]

A recent study conducted at the National Kidney and Transplant Institute in Quezon City, Philippines, has found that hemoperfusion, a novel adjunct therapy, is effective in improving the survival rate of leptospirosis patients with renal failure and shock. The study compared the outcomes of patients receiving standard medical therapy alone to those receiving standard medical therapy with hemoperfusion. The hemoperfusion group showed a 36.84% reduction in 28-day mortality, as well as improvements in inflammatory markers, hemodynamics, and renal and pulmonary function. The study concludes that hemoperfusion is a safe and effective therapy for managing severe sepsis and improving patient survival. [Extracted from the article]

Researchers at Baskent University Faculty of Medicine in Ankara, Turkey have described a case of oxaliplatin-induced immune thrombocytopenia in a patient with stage 4 pancreatic cancer. The 55-year-old man developed immune thrombocytopenia during his 18th cycle of chemotherapy. Despite treatment with methylprednisolone and platelet infusion, his platelet count remained low. However, subsequent plasmapheresis and continued steroid therapy resulted in a gradual improvement in platelet count and resolution of symptoms. The researchers emphasize the importance of considering immune thrombocytopenia in patients receiving oxaliplatin-based chemotherapy and suggest further research is needed to determine the optimal management of this rare complication. [Extracted from the article]

A patent application has been submitted for a method of using plasmapheresis to improve the health status of individuals suffering from age-related disorders. The method involves measuring various health indicators before and after plasmapheresis treatment, such as strength, balance, mental status, and walking ability, to determine if the treatment has been effective. The patent application also describes using plasmapheresis to modulate the expression of cell surface markers on white blood cells. The method can be administered over multiple treatment sessions or a single session, and the treatment can be repeated until the desired improvement is achieved. [Extracted from the article]

A recent study conducted at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, has examined the effects of anabolic androgenic steroids (AASs) on the liver. The study found that AASs can cause various forms of liver injury, including a rare cholestatic syndrome with bland histology. In cases where conventional pharmacotherapeutic measures fail to alleviate symptoms, plasmapheresis may provide long-lasting relief. The study highlights the need for caution and awareness regarding the misuse of AASs, particularly among amateur athletes seeking cosmetic and performance-enhancing effects. [Extracted from the article]

A clinical trial, NCT06571552, is being conducted to examine the effects of therapeutic plasmapheresis on blood clotting. The trial aims to understand the changes in coagulation factors and their regeneration after plasmapheresis sessions. Researchers also want to determine the relationship between fibrinogen levels and the risk of bleeding after plasmapheresis. The trial involves various tests and measurements, including fibrinogen levels, blood cell counts, and clotting factor levels, taken before and after plasmapheresis sessions. The results of these tests provide valuable information about the impact of plasmapheresis on blood parameters. [Extracted from the article]

The article reports on a patent application for "Compositions and Methods for Plasmapheresis" submitted by Dobri Kiprov. Topics include the method for improving health through plasmapheresis by assessing changes in strength, balance, mental status, and walking ability, as well as modulating cell surface markers on white blood cells.

The article describes a case study of a patient with stiff-person syndrome (SPS) treated successfully with plasmapheresis. Topics discussed include the autoimmune nature of SPS and its symptoms, including muscle stiffness and psychiatric issues, and the effectiveness of plasmapheresis as a treatment option.

A new study conducted at the Shandong Provincial Hospital in China evaluated the clinical efficacy of HA380 hemoperfusion (HP) in the treatment of septic shock. The study analyzed the data of 41 patients with septic shock and found statistically significant differences in various clinical parameters before and after HP treatment. The researchers concluded that HP can improve the clinical efficacy of patients with septic shock by improving hemodynamics, reducing lactic acid levels and infection indexes, and alleviating organ function damage. This study provides valuable insights for the treatment of septic shock. [Extracted from the article]

A study conducted at Saint John Regional Hospital examined the treatment of a severe case of carbamazepine overdose using hemodialysis, plasmapheresis, and neostigmine. Carbamazepine is a medication used for various indications, and its toxicity can be delayed and persistent despite supportive care. In this case, symptoms of overdose persisted for several days until bowel evacuation was administered along with neostigmine, hemodialysis, and plasmapheresis. The study found that multidose activated charcoal and whole bowel irrigation may have been necessary for more effective treatment. This case report is one of the few to utilize both hemodialysis and plasmapheresis for carbamazepine overdose and the only one to successfully administer neostigmine to remove the drug via the gastrointestinal tract. [Extracted from the article]

A recent report from the Chinese Academy of Medical Sciences examines the characteristics and mobility of individuals who participate in both voluntary blood donation and plasmapheresis donation. The study compares data from two counties in Guangyuan, Sichuan Province, and finds that there is a small overlap of individuals who donate both blood and plasma. The majority of these donors are men aged 40 to 50, and people over 50 years old are more likely to shift their donation goals. The research concludes that most donors have a single and fixed donation goal and are not easily swayed to change. [Extracted from the article]

A study conducted by researchers from the Chinese Academy of Medical Sciences aimed to analyze the impact of setting up a plasmapheresis station on the collection volume of voluntary blood donation in China. The study used data collected from blood stations in Guangyuan, Sichuan Province, from 2011 to 2021, as well as plasma collection data from two plasmapheresis stations in the region. The results showed that while the establishment of a new plasmapheresis station had a short-term impact on blood collection volume, it did not have a statistically significant effect on voluntary blood donation collection in the long term. The study concluded that the findings could provide scientific reference for the management policies of blood stations and plasmapheresis stations in China. [Extracted from the article]

A study conducted by the Chinese Academy of Medical Sciences investigated the bone density and bone metabolism of plasmapheresis donors in China. The study found that plasmapheresis donation does not negatively impact the bone health of donors or increase the risk of osteoporosis. However, it was observed that the osteogenic activity of plasmapheresis donors increased. The researchers recommend that middle-aged and elderly plasmapheresis donors supplement their vitamin D intake appropriately. [Extracted from the article]

The article focuses on the effectiveness of hemoperfusion (HP) for treating dermatomyositis-associated acute exacerbation of interstitial lung disease, as investigated by researchers at Affiliated Hospital of Qingdao University. Topics include the significant improvements in oxygenation and hemodynamic parameters after HP treatment, the reduction in inflammatory cytokine levels, and the shorter ICU stays and lower mortality rates observed in the treatment group compared to the control group.

The article highlights the patent application number USPTO 12048794 for a device designed for therapeutic plasma exchange, issued to Grifols Worldwide Operations Limited on August 22, 2024. It also discusses the device's ability to simultaneously administer therapeutic drugs during plasma exchange, improvements in device portability, and solutions to problems with prior TPE devices.

A recent study from the University of Texas McGovern Medical School highlights the case of a 79-year-old man with metastatic renal cell carcinoma who experienced diaphragmatic myopathy after receiving immune checkpoint inhibitor (ICI) cancer treatment. The patient developed shortness of breath and respiratory insufficiency, and subsequent tests revealed elevated levels of certain enzymes and muscle weakness. Treatment included various medications and therapies, but unfortunately, the patient passed away due to recurrent infections. The study emphasizes the importance of multidisciplinary management and early identification of immune-related adverse events (irAEs) in patients receiving ICIs. [Extracted from the article]

Researchers from the National Hospital of Sri Lanka have reported a case of a 21-year-old man with dengue fever who developed severe rhabdomyolysis and acute kidney injury. Despite traditional treatments, the patient's condition worsened until the addition of CytoSorb(R) adsorber as an adjunct therapy to continuous venovenous hemodiafiltration. This resulted in a significant reduction in creatinine phosphokinase and myoglobin levels, leading to complete renal recovery. The study suggests that CytoSorb(R) adsorber may have potential benefits in removing high-molecular-weight proteins such as myoglobin in cases of dengue-related rhabdomyolysis. [Extracted from the article]

A recent report from Minia University discusses the challenges associated with plasmapheresis, a procedure used in healthcare. The study aimed to determine the effectiveness of an educational and training program on nurses' competency in performing plasmapheresis. The findings showed that the program significantly improved nurses' knowledge and competency-based practice in the technique. The research suggests that regular implementation of competency training programs and integration of quality and safety education in nursing curricula can enhance nurses' proficiency in healthcare settings. [Extracted from the article]

A recent study conducted in Xi'an, China explored the factors associated with the refusal of hemoperfusion (HP) treatment in patients with acute paraquat poisoning. The study analyzed data from 358 patients and found that elderly individuals and those with a history of mental disorders were more likely to refuse HP treatment. Patients who refused HP had a higher mortality rate compared to those who received the treatment. This research highlights the importance of addressing these factors to improve treatment outcomes for patients with acute paraquat poisoning. [Extracted from the article]

A patent application has been submitted for a system and method that aims to improve the accuracy of platelet collection procedures. The system involves separating blood into its components using centrifugation or spinning membrane separation. The collected platelet concentrate can then be adjusted to achieve the desired target concentration. The patent application provides detailed technical specifications and claims for the device, which includes a pump system, valve system, centrifugal separator, spinning membrane separator drive unit, and a controller. [Extracted from the article]

A patent application has been submitted for a control component that aims to securely control a medical device, specifically a dialysis machine. The control component includes an input interface, an output interface, a processor, and at least one operating element. The processor assigns additional functions to the operating element to confirm the execution of control commands. The control component can be operated separately from the medical device and communicates with it through a secure connection. The patent application emphasizes the importance of safety requirements in medical devices and the need to prevent misuse of protected health information and unintended influence on device control. [Extracted from the article]

A report from University Hospital Caremeau in Nimes, France discusses research findings on bullous pemphigoid, an autoimmune blistering disease. The disease is most common in individuals over the age of 70 and is associated with a 23.5% 1-year mortality rate, particularly in diabetics or those with ischemic heart disease and high anti-BP-180. Treatment typically involves topical steroids, but some patients may require oral steroids and systemic immunosuppression. The report highlights a successful case of a diabetic patient on chronic hemodialysis who was treated with therapeutic plasmapheresis, avoiding the need for systemic steroids. [Extracted from the article]

A research study conducted at Tongji University in Shanghai, China has developed a new method for treating sepsis, a potentially life-threatening condition caused by pathogens and toxins in the bloodstream. The researchers created an ultrasound-responsive microbowl coated with hybrid cell membranes that can selectively eliminate pathogens, toxins, and heavy metal ions from the blood. The microbowl's structure allows for increased adsorption efficiency and its coating enhances biocompatibility and blood circulation. The study found that the microbowl was effective in removing endotoxins, bacteria, and heavy metal ions from the bloodstream. [Extracted from the article]

A study conducted at Tan Tock Seng Hospital in Singapore has reported on a case of a patient with anti-melanoma differentiation-associated 5 gene autoantibody (anti-MDA5) positive dermatomyositis (DM) with rapidly progressive interstitial lung disease (RP-ILD). This form of autoimmune myositis is difficult to treat and has low survival rates. The patient initially received intensive combination therapy but eventually responded to intravenous daratumumab, an anti-CD38 monoclonal antibody. The use of daratumumab led to clinical and biochemical improvement in the patient. This case suggests that daratumumab may be a potential treatment option for refractory autoimmune conditions. [Extracted from the article]

A study conducted in Gurgaon, India, examined the long-term outcomes of diffuse alveolar hemorrhage (DAH) in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). DAH is a life-threatening condition characterized by symptoms such as hemoptysis, cough, breathlessness, and respiratory failure. The study included 133 AAV patients, of whom 31.5% had DAH. The study found that timely diagnosis and aggressive management, including a combination of pulse steroids, cyclophosphamide/rituximab, and plasmapheresis, were crucial for better outcomes. The study also reported a mortality rate of 16.6% and morbidity in 38% of cases. [Extracted from the article]

A patent has been issued to Fenwal Inc. for systems and methods that increase the volume of Immunoglobulin G (IgG) collected during plasmapheresis procedures. Plasmapheresis is a process where whole blood is withdrawn from a donor, the plasma is separated from the cellular blood components, and the cellular blood components are returned to the donor. The patent describes a method that maximizes the volume of whole blood processed during the first draw phase, resulting in increased IgG collection. This innovation could lead to higher volumes of IgG being produced at plasma collection centers, benefiting patients who require plasma-derived therapies. [Extracted from the article]

A research study conducted at Kyushu University has provided insights into the management of trismus, a condition characterized by limited mouth opening, in a patient with Isaacs' syndrome. Isaacs' syndrome is a rare disorder that affects the peripheral nervous system and presents with symptoms such as cramps and fasciculations. The patient in this case report experienced pain and swelling in the gingiva surrounding his lower first molar, but dental treatment was initially deemed impossible due to the presence of Isaacs' syndrome. However, after undergoing plasmapheresis treatment, which temporarily reduced trismus, dental interventions became feasible. This case highlights the importance of collaboration between neurologists and dentists in similar cases and provides valuable insights for dental treatment planning. [Extracted from the article]

Researchers from the Sanjay Gandhi Postgraduate Institute of Medical Sciences in Uttar Pradesh, India, conducted a study on the effect of intravenous immunoglobulin (IVIg) and plasmapheresis (PLEX) on nerve conduction studies (NCS) in patients with Guillain-Barre Syndrome (GBS). The study included 72 GBS patients and found that IVIg and PLEX treatment resulted in a reduction in conduction block and axonal burden. The research suggests that IVIg and PLEX may be beneficial in improving nerve conduction parameters in GBS patients. The study was published in the Journal of Clinical Neuroscience. [Extracted from the article]

Lyfspn Inc. has been issued a patent for compositions and methods for plasmapheresis. The patent describes a method of providing plasmapheresis to an individual in order to improve their health status. The method involves measuring various factors such as strength, balance, mental status, and walking ability before and after the administration of plasmapheresis, and comparing the pre- and post-treatment health status to determine improvement. The patent also discusses using plasmapheresis to treat conditions associated with aging and modulating the expression of cell surface markers on white blood cells. The method can be repeated until a specific value or change is achieved. [Extracted from the article]

Researchers from Northeast Normal University in Changchun, China have developed a new method for efficiently removing excess bilirubin, a bile pigment, from the blood. Traditional adsorbents used for this purpose have been found to have poor adsorption performance and blood compatibility. The researchers used a rational design strategy guided by density functional theory calculations to create blood-compatible nanofiber adsorbents with quaternary ammonium groups. These nanofiber adsorbents demonstrated a bilirubin removal efficiency above 90% even in the presence of high concentrations of albumin. The study suggests that this theory-driven design method has potential for the development of effective bilirubin adsorbents in hemoperfusion applications. [Extracted from the article]

A clinical trial is underway to test the safety and effectiveness of a single dose of eculizumab in preventing antibody-mediated rejection (AMR) in kidney transplant patients with incompatible blood types. The trial aims to expand the pool of potential donors by allowing recipients to receive kidneys from donors with different blood types. Eculizumab, a drug that targets the complement system, may help prevent AMR in these cases. The trial is currently recruiting participants and is expected to be completed by December 2025. [Extracted from the article]

A case report from researchers at Ilam University of Medical Sciences in Iran discusses the effects of Aluminum Phosphide (ALP) poisoning on the human body. ALP is a highly toxic pesticide that can cause damage to various organs, including the heart, lungs, gastrointestinal tract, kidneys, and central nervous system. The report describes a 53-year-old man who developed Hemolytic Uremic Syndrome (HUS) and Acute Kidney Injury (AKI) as a result of ALP poisoning. The patient received supportive treatments such as hemodialysis and plasmapheresis and fully recovered after 23 days of hospitalization. The researchers suggest that a combination of hemodialysis and plasmapheresis can improve outcomes in patients with ALP toxicity. [Extracted from the article]

A recent study conducted at Sichuan University in Chengdu, China, has reported new findings on the treatment of sepsis caused by Gram-positive bacterial infections. The researchers designed poly (sulfobetaine methacrylate-co-diallyldimethylammonium)/red blood cell membrane (PSDR) hydrogel microspheres as hemoperfusion adsorbents to attract bacteria and adsorb toxins released by the bacteria. The PSDR microspheres demonstrated excellent and rapid adsorption of bacterial toxins, with a 75.6% removal efficiency in just 10 minutes. This research offers potential new solutions for the deep treatment of bacteria-induced sepsis. [Extracted from the article]